Released May 13, 2021, after the close
10-Q filed May 13, 2021, 43 days after period end · 0001390478-21-000017
Q1 2021 · 10-Q
Revenue$5.70M$5.70M — vs Q1 2020+200.0% vs Q4 2020
Net Income-$2.40M-$2.40M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.16-$0.16 N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$2,245,000N/M
Operating Cash Flow-$10,269,000N/M
Margins · derived
Operating margin-39.4%
Net margin-42.2%
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $5.70M | $0.00 | — | — |
| Net Income | -$2.40M | -$4.14M | -$4.54M | -$8.00M |
| EPS Diluted | -$0.16 | -$0.66 | -$11.12 | -$1.67 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR